B

BioInvent International AB
STO:BINV

Watchlist Manager
BioInvent International AB
STO:BINV
Watchlist
Price: 28.55 SEK 1.78% Market Closed
Market Cap: 1.9B SEK

Operating Margin

-142.2%
Current
Improving
by 377.9%
vs 3-y average of -520.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-142.2%
=
Operating Income
kr-348.1m
/
Revenue
kr244.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-142.2%
=
Operating Income
kr-348.1m
/
Revenue
kr244.8m

Peer Comparison

Country Company Market Cap Operating
Margin
SE
BioInvent International AB
STO:BINV
1.9B SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.5B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 86% of companies in Sweden
Percentile
14th
Based on 2 047 companies
14th percentile
-142.2%
Low
-2 025 693.8% — -1.8%
Typical Range
-1.8% — 12.5%
High
12.5% — 10 459.2%
Distribution Statistics
Sweden
Min -2 025 693.8%
30th Percentile -1.8%
Median 6%
70th Percentile 12.5%
Max 10 459.2%

BioInvent International AB
Glance View

Market Cap
1.9B SEK
Industry
Biotechnology

BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

BINV Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-142.2%
=
Operating Income
kr-348.1m
/
Revenue
kr244.8m
What is BioInvent International AB's current Operating Margin?

The current Operating Margin for BioInvent International AB is -142.2%, which is above its 3-year median of -520.1%.

How has Operating Margin changed over time?

Over the last 3 years, BioInvent International AB’s Operating Margin has decreased from -16.3% to -142.2%. During this period, it reached a low of -1 179.3% on Sep 30, 2024 and a high of -15.5% on Dec 31, 2022.

Back to Top